SNPX Synaptogenix Forward P/S Multiple
Synaptogenix, Inc. (SNPX) is implementing advanced neuron regeneration methods to combat Alzheimer's disease. Business prospects rely on successful briobstatine-1 tests and the influx of external funding. The operating model is based on engaging certified CROs to conduct research. The forward P/S ratio demonstrates valuation dynamics, where the 0.00 mark serves as a key metric for analyzing market expectations.
Synaptogenix, Inc - analytical breakdowns and key metrics (SNPX)
- current price and projected stock value:
- market capitalization data:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Synaptogenix, Inc.|SNPX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Synaptogenix, Inc.|SNPX - Aggregate Debt Obligations|Debts to Book Capitalization Synaptogenix, Inc|SNPX - Long-Term Debt Volume|Company Short-Term Debt Synaptogenix|Quick Ratio synaptogen.com
- business earnings and investment ratios data:
SNPX - Net Income|Future Profit Synaptogenix, Inc.|SNPX - Business Payback Period|Future Price to Earnings Neurotrope|SNPX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Synaptogenix, Inc|SNPX - Operating profit before amortization|Earnings per share for the last twelve months Synaptogenix|SNPX - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months synaptogen.com|SNPX - Earnings per share growth this year|Net earnings per share growth forecast for next year Synaptogenix, Inc.
- sales and revenue indicators:
Summary company analysis:Synaptogenix SNPX
Synaptogenix, Inc. (SNPX) successes in clinical trials for Alzheimer's disease treatments lay the foundation for capturing the colossal unmet demand of an aging population. The forward P/S history reflects the ratio of current market capitalization to projected revenue, allowing for an assessment of market expectations for future sales and determining whether the asset's quotes possess a margin of safety or are overbought.
Analysis of competing companies
Forward P/S Multiple BIIB (Biogen)|Projected Price to Revenue Neurocrine|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Denali Corp - Market Cap to Projected Revenue|Harmony Biosciences - Forward Price-to-Revenue Multiple|Forward Price to Sales BHVN|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AVXL|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prothena Corporation (PRTA)|Forward Price-to-Revenue Multiple ALEC (Alector, Inc.)|Market Cap to Expected Sales Ratio Annexon Biosciences|Price-to-Projected Revenue Ratio Omeros OMER|Market Cap to Expected Sales Ratio Neurogene Therapeutics (NGNE)|ACIU - Price-to-Projected Revenue Ratio|VYGR (voyagertherapeutics.com) - Market Cap to Projected Revenue|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Future Price to Revenue SCLX (Scilex Holding)|Forward Price-to-Revenue Multiple TVGN|Market Cap to Projected Revenue ACOG (Alpha Cognition Corp)|Price-to-Projected Revenue Ratio Cognition Therapeutics (CGTX)|inhibikase.com - Market Cap to Projected Revenue|Forward P/S Multiple SAVA (Cassava Sciences)|Assertio Holdings (ASRT) - Market Cap to Future Revenue Ratio|COYA: Forward Price-to-Revenue Multiple|VTGN - Forward P/S Multiple|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|acumenpharm.com - Forward Price to Sales|Price-to-Projected Revenue Ratio CervoMed|Market Cap to Future Revenue Ratio Alterity Therapeutics Ltd ATHE|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|Market Cap to Expected Sales Ratio pepgen.com|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|relmada.com (RLMD) - Market Cap to Future Revenue Ratio|ANVS - Price-to-Projected Revenue Ratio|GRCE (Grace Therapeutics, Inc.) - Market Cap to Projected Revenue|AIFF: Forward P/S Multiple|Klotho Neurosciences (KLTO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|revivapharma.com - Future Price to Revenue|Forward Price-to-Revenue Multiple MTVA (MetaVia Inc)|Price to Expected Revenue Ratio NRXS|Price-to-Projected Revenue Ratio Helius Medical Technologies HSDT|Passage Bio Inc. (PASG) - Market Cap to Future Revenue Ratio|Neuphoria - Forward P/S Multiple|Projected Price to Revenue minervaneurosciences.com (NERV)|ATHA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Addex Therapeutics Ltd. (ADXN)|Price-to-Projected Revenue Ratio Alzamend Neuro Inc.|Market Cap to Projected Revenue CYCN (Cyclerion)|Forward P/S Multiple PTIX|Market Cap to Expected Sales Ratio pasitheaclinics.com|Cortigent - Forward Price-to-Revenue Multiple|ATXI: Market Cap to Projected Revenue|BCLI: Forward Price-to-Revenue Multiple|Forward Price to Sales CARA (Cara Therapeutics Inc)|CHRO: Forward P/S Multiple|ELYM - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Intra-Cellular Therapies Inc.|Market Cap to Projected Revenue LBPH (Longboard Pharmaceuticals Inc)|Forward P/S Multiple MRNS|Forward Price-to-Revenue Multiple NKGen Biotech Corp NKGN|NeuroBo Pharmaceuticals - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio sagerx.com (SAGE)|TRVN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Vigil Neuroscience VIGL|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CERE
